Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;12(3):2166-2176.
doi: 10.1002/ehf2.15236. Epub 2025 Feb 4.

Right ventricular dysfunction for prediction of long-term recovery in de novo HFrEF : a PROLONG-II substudy

Affiliations
Randomized Controlled Trial

Right ventricular dysfunction for prediction of long-term recovery in de novo HFrEF : a PROLONG-II substudy

Aiste Monika Jakstaite et al. ESC Heart Fail. 2025 Jun.

Abstract

Aims: To analyse the predictive value of advanced markers of right ventricular (RV) function and RV-pulmonary arterial (PA) coupling in forecasting long-term left ventricular (LV) improvement in de novo heart failure with reduced ejection fraction (HFrEF).

Methods and results: 260 patients (mean age 57 years, 68% men) from the PROLONG-II study were included. PROLONG-II analysed patients with new-onset HFrEF receiving a wearable cardioverter-defibrillator. For this substudy, RV free wall longitudinal strain (RVFWS), tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), and right ventricular-pulmonary artery (RV-PA) coupling ratios [RVFWS/systolic pulmonary artery pressure (PASP), TAPSE/PASP and FAC/PASP] at baseline and 3-month follow-up (early follow-up) were examined. LV improvement and non-improvement were defined as an LV ejection fraction (LVEF) of >35% or ≤35% at last available (long-term) follow-up. The median follow-up was 31.5 months (IQR: 18.2-45.4), and 151 (58%) patients experienced LV improvement in the long term. No significant differences of RV function and markers of RV-PA coupling were observed at baseline; however, the subgroup of patients with long-term LVEF improvement showed better RV function at early follow-up (RVFWS -20.9 ± 4.3 vs. -18.5 ± 5.1%, TAPSE 19.7 ± 5.1 vs. 17.4 ± 4.9 mm, FAC 39.7 ± 8.5 vs. 35.2 ± 9.4%, all P < 0.01). In multivariable analysis, RVFWS at early follow-up was shown to be an independent predictor of later LV recovery [odds ratio 1.078 (95% confidence interval 1.010-1.150), P < 0.05]. The non-improvers exhibited worse RV-PA coupling at early follow-up [RVFWS/PASP 0.82 ± 0.35 vs. 0.65 ± 0.35%/mmHg, TAPSE/PASP 0.71 (0.55-1.00) vs. 0.54 (0.35-0.75) mm/mmHg, FAC/PASP 1.54 ± 0.61 vs. 1.24 ± 0.75%/mmHg, all P < 0.01]. RVFWS/PASP identified RV-PA uncoupling was associated with a higher risk of all-cause mortality (hazard ratio 4.64, 95% confidence interval 1.34-16.09, P = 0.033).

Conclusions: Persistent RV dysfunction, as indicated by both standard and advanced echocardiographic markers during the early follow-up period, implies a reduced potential for long-term LV recovery in patients with newly diagnosed HFrEF.

Keywords: Heart failure; Right ventricular free wall longitudinal strain; Right ventricular function; Right ventricular‐pulmonary arterial coupling; Speckle‐tracking echocardiography.

PubMed Disclaimer

Conflict of interest statement

H.A.K.H. received modest lecture honorary and/or a fellowship grant from AstraZeneca, Zoll, and Boston Scientific. J.M. received modest lecture honorary, travel grants, and/or a fellowship grant from Abbott, Biotronik, Boston Scientific, and Zoll. J.E. received a fellowship grant from Biotronik. C.V. received honorary for lectures or consulting from Abbott, Medtronic, and Zoll. J.B. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, Norgine, Edwards, and Roche not related to this article; and research support for the department from Zoll, CVRx, Abiomed, Norgine, and Roche, not related to this article. D.D. received modest lecture honorary, travel grants, and/or a fellowship grant from Abbott, AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CVRx, Medtronic, Microport, Pfizer, Sanofi, and Zoll. D.B. received honoraria for lectures/consulting from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, and Pfizer. All other authors: none declared.

Figures

Figure 1
Figure 1
LVEF changes in subgroups with and without RV‐PA uncoupling as evaluated by RVFWS/PASP at baseline, early 3‐month, and last available follow‐up. LVEF, left ventricular ejection fraction; RV, right ventricular, RVFWS/PASP, ratio between right ventricular free wall longitudinal strain and pulmonary artery systolic pressure.
Figure 2
Figure 2
Kaplan–Meier survival curves according to RV‐PA coupling. (A) Survival analysis according to RVFWS/PASP (cut‐offs >0.71 vs. ≤0.71%/mmHg). (B) Survival analysis according to TAPSE/PASP (cut‐offs ≥0.67 vs. <0.67 mm/mmHg). (C) Survival analysis according to FAC/PASP (cut‐offs >1.41 vs. ≤1.41%/mmHg). FAC/PASP, ratio between fractional area change and pulmonary artery systolic pressure; RVFWS/PASP, ratio between right ventricular free wall longitudinal strain and pulmonary artery systolic pressure; RV‐PA, right ventricular‐pulmonary artery; TAPSE/PASP, ratio between tricuspid annular plane systolic excursion ratio and pulmonary artery systolic pressure.

Similar articles

References

    1. Lundorff IJ, Sengelov M, Pedersen S, Modin D, Bruun NE, Fritz‐Hansen T, et al. Prognostic value of right ventricular echocardiographic measures in patients with heart failure with reduced ejection fraction. J Clin Ultrasound 2021;49:903‐913. doi:10.1002/jcu.23050 - DOI - PubMed
    1. Carluccio E, Biagioli P, Alunni G, Murrone A, Zuchi C, Coiro S, et al. Prognostic value of right ventricular dysfunction in heart failure with reduced ejection fraction: superiority of longitudinal strain over tricuspid annular plane systolic excursion. Circ Cardiovasc Imaging 2018;11:e006894. doi:10.1161/CIRCIMAGING.117.006894 - DOI - PubMed
    1. Dini FL, Carluccio E, Simioniuc A, Biagioli P, Reboldi G, Galeotti GG, et al. Right ventricular recovery during follow‐up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail 2016;18:1462‐1471. doi:10.1002/ejhf.639 - DOI - PubMed
    1. Houard L, Benaets MB, de Meester de Ravenstein C, Rousseau MF, Ahn SA, Amzulescu MS, et al. Additional prognostic value of 2D right ventricular speckle‐tracking strain for prediction of survival in heart failure and reduced ejection fraction: a comparative study with cardiac magnetic resonance. JACC Cardiovasc Imaging 2019;12:2373‐2385. doi:10.1016/j.jcmg.2018.11.028 - DOI - PubMed
    1. Carluccio E, Biagioli P, Lauciello R, Zuchi C, Mengoni A, Bardelli G, et al. Superior prognostic value of right ventricular free wall compared to global longitudinal strain in patients with heart failure. J Am Soc Echocardiogr 2019;32:836‐844.e1. doi:10.1016/j.echo.2019.02.011 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources